CO2022009239A2 - Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα e il-23 - Google Patents

Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα e il-23

Info

Publication number
CO2022009239A2
CO2022009239A2 CONC2022/0009239A CO2022009239A CO2022009239A2 CO 2022009239 A2 CO2022009239 A2 CO 2022009239A2 CO 2022009239 A CO2022009239 A CO 2022009239A CO 2022009239 A2 CO2022009239 A2 CO 2022009239A2
Authority
CO
Colombia
Prior art keywords
variable domains
polypeptides
immunoglobulin variable
single immunoglobulin
present technology
Prior art date
Application number
CONC2022/0009239A
Other languages
English (en)
Inventor
Heidi Rommelaere
Ann Brigé
Sigrid Cornelis
Eric Lorent
Christian Asbrand
Original Assignee
Sanofi Sa
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Ablynx Nv filed Critical Sanofi Sa
Publication of CO2022009239A2 publication Critical patent/CO2022009239A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente tecnología tiene como objetivo proporcionar un tipo novedoso de fármaco. Específicamente, la presente tecnología proporciona polipéptidos que comprenden al menos tres dominios variables únicos de inmunoglobulina (ISVD), caracterizados por que al menos un ISVD se une a TNFα y al menos dos ISVD se unen a IL-23. La presente tecnología también proporciona ácidos nucleicos, vectores y composiciones.
CONC2022/0009239A 2019-12-06 2022-07-01 Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα e il-23 CO2022009239A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944619P 2019-12-06 2019-12-06
EP20305056 2020-01-23
EP20000090 2020-02-28
EP20305216 2020-03-02
PCT/EP2020/084430 WO2021110816A1 (en) 2019-12-06 2020-12-03 POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23

Publications (1)

Publication Number Publication Date
CO2022009239A2 true CO2022009239A2 (es) 2022-07-29

Family

ID=73642903

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0009239A CO2022009239A2 (es) 2019-12-06 2022-07-01 Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα e il-23

Country Status (13)

Country Link
US (4) US20210188963A1 (es)
EP (1) EP4069733A1 (es)
JP (1) JP2023505492A (es)
KR (1) KR20220122652A (es)
CN (1) CN114981300A (es)
AU (1) AU2020396204A1 (es)
BR (1) BR112022009799A2 (es)
CA (1) CA3163877A1 (es)
CO (1) CO2022009239A2 (es)
IL (1) IL293561A (es)
MX (1) MX2022006880A (es)
TW (1) TW202134269A (es)
WO (1) WO2021110816A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230053002A (ko) 2014-05-16 2023-04-20 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
PL1888641T3 (pl) 2005-05-18 2012-05-31 Ablynx Nv Białka wiążące albuminę surowicy
EP2010568A1 (en) 2006-04-14 2009-01-07 Ablynx N.V. Dp-78-like nanobodies
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
CA2839779C (en) 2011-06-23 2020-10-06 Ablynx Nv Serum albumin binding proteins
HUE031828T2 (en) 2011-06-23 2017-08-28 Ablynx Nv Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain
KR20230053002A (ko) 2014-05-16 2023-04-20 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
CN108473579B (zh) * 2015-10-22 2022-03-01 埃博灵克斯股份有限公司 Gitr激动剂
NO2768984T3 (es) 2015-11-12 2018-06-09
CN115925919A (zh) 2015-11-13 2023-04-07 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
CN108473564B (zh) 2015-11-18 2022-04-08 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
US10975141B2 (en) * 2016-02-12 2021-04-13 Ablynx N.V. Method for the production of immunoglobulin single variable domains
CN110049997B (zh) 2016-12-07 2023-09-22 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
CN117285623A (zh) 2017-01-17 2023-12-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
JP7300385B2 (ja) 2017-01-17 2023-06-29 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG

Also Published As

Publication number Publication date
WO2021110816A1 (en) 2021-06-10
EP4069733A1 (en) 2022-10-12
KR20220122652A (ko) 2022-09-02
US20220363747A1 (en) 2022-11-17
US11332525B2 (en) 2022-05-17
CA3163877A1 (en) 2021-06-10
MX2022006880A (es) 2022-07-11
CN114981300A (zh) 2022-08-30
US20220064281A1 (en) 2022-03-03
IL293561A (en) 2022-08-01
JP2023505492A (ja) 2023-02-09
BR112022009799A2 (pt) 2022-08-16
AU2020396204A1 (en) 2022-07-28
US20210188963A1 (en) 2021-06-24
TW202134269A (zh) 2021-09-16
US20220372128A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
AR120698A1 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
CO2018009533A2 (es) Conjugados de amanitina
CO2022008813A2 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
EA201990861A1 (ru) Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
CO2022008576A2 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα y ox40l
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
AR103488A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
EA202091976A1 (ru) Вариабельные домены антител, нацеленные на cd33, и их применение
DOP2019000011A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
BR112019008859A2 (pt) anticorpos direcionados contra a morte programada 1 (pd-1)
PE20150023A1 (es) Proteinas de union a antigeno st2
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
CO2022009239A2 (es) Polipéptidos que comprenden dominios variables únicos de inmunoglobulina dirigidos a tnfα e il-23
EA201890587A1 (ru) Композиции и способы для лечения боли
EA201892522A1 (ru) Днк-моноклональные антитела, нацеленные на молекулы контрольных точек
CR20190193A (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
BR112015022780A2 (pt) reticuladores de produto químico
CO2019012204A2 (es) Proteínas de unión al antígeno anti-jagged1
CO2023009231A2 (es) Polipéptidos que comprenden dominios variables simples de inmunoglobulina dirigidos a glypican-3 y al receptor de células t
EA201591279A1 (ru) Новые фрагменты антител, их композиции и способы применения
BR112022000481A2 (pt) Conjuntos de anticorpos e de ácidos nucleicos, vetor de expressão, célula hospedeira e métodos de pré-direcionamento de radioimunoterapia e de direcionamento de um radioisótopo